The fast growth of cell and gene therapies has made it difficult for the global industry to keep up with talent requirements. The volume of clinical trials around the world—approximately 1,200 at this time1—puts pressure on manufacturers to scale-up the production of cells and viral vectors. CellCAN, a knowledge mobilization network in cell and gene therapies (CGTs), and CCRM, a leader in developing and commercializing regenerative medicine-based technologies and CGTs, are responding to that cha...